Ineficácia in vivo da terbinafina em leishmaniose cutânea causada por Leishmania (Leishmania) amazonensis em camundongos C57BL/6

Sampaio, Raimunda Nonata Ribeiro; Takano, Gustavo Henrique Soares; Malacarne, Ana Cristina Barbieri; Pereira, Tércio Rodrigues; Magalhães, Albino Verçosa de

doi:10.1590/s0037-86822003000400018

Cited by 7 publications

(2 citation statements)

References 10 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these diseases, cutaneous leishmaniasis (CL) is particularly important in South America because of its chronicity, latency, and the potential to develop metastases that can lead to disfiguring lesions. Chemotherapy with pentavalent antimonial compounds is extensively used to treat this illness; however, its adverse effects, such as parenteral administration, extended treatment regimens, and the appearance of resistance warrant a search for alternative drugs that can be more 10,21 effective .…”

Section: Introductionmentioning

confidence: 99%

Potencial anti-Leishmania e imunomodulador dos extratos de Campsiandra laurifolia Benth. (Fabaceae)

Chagas¹,

Müller

Soares

et al. 2010

Rev Pan-Amaz Saude

View full text Add to dashboard Cite

Infusions of leaves, bark and seeds of Campsiandra laurifolia Benth. (Fabaceae) are used by communities of AfricanAmerican descendants of slaves (quilombolas) mainly for treatment of cutaneous leishmaniasis (CL), wounds, ulcers and tinea. Hydroalcoholic and aqueous extracts of C. laurifolia were investigated for anti-Leishmania activity on promastigotes and amastigotes of Leishmania (L.) amazonensis and immunomodulatory responses, including cell proliferation of splenocytes and NO production by peritoneal macrophages from BALB/c mice. The hydroalcoholic extracts of the bark and the aqueous extracts of the leaves and seeds presented a reduced activity against amastigotes and promastigotes (<20%), and the same result was observed for the inhibition of NO production by activated macrophages (<23%). Most of the extracts displayed a moderate immunosuppressive potential (32.6 to 38.5%); on the other hand, the aqueous extracts of seeds inhibited up to 87% of the growth of splenocytes of BALB/c mice stimulated with mitogens. Such activity may explain the use of C. laurifolia for the treatment of CL by quilombolas. Its use may not be mainly associated with a direct action on the parasite but with an anti-inflammatory activity because such activity decreases the tissue damage caused by the immune system in response to the infection and, consequently, aids the healing process of leishmanial lesions.

show abstract

Section: Introductionmentioning

confidence: 99%

Potencial anti-Leishmania e imunomodulador dos extratos de Campsiandra laurifolia Benth. (Fabaceae)

Chagas¹,

Müller

Soares

et al. 2010

Rev Pan-Amaz Saude

View full text Add to dashboard Cite

show abstract

“…A controversial result was observed in experimental models of cutaneous leishmaniasis, the treatment with terbinafine of L. major-innfected BALB/c mice was effective in reducing lesions, while in the model L. amazonensis-infected C57Bl/6 mice, this drug led to no significant reduction of both lesion size or parasite load when compared to the untreated control group (48,49). In the in vivo models of visceral infection, treatment of hamsters infected with L. infantum chagasi with terbinafine did not cause a difference in weight or spleen parasite load compared to the untreated control, with a significant decrease only observed when the drug was associated with glucantime (50,51).…”

Section: Antifungalsmentioning

confidence: 98%

Leishmaniasis treatment update of possibilities for drug repurposing

Torres-Santos¹

2018

Front Biosci

View full text Add to dashboard Cite

The leishmaniases represent a public health problem in under-developed countries and are considered a neglected disease by the World Health Organization (WHO). They are cuased by parasites with different clinical manifestations. Currently, there is no vaccine, and treatment is in-efficient and is associated with both serious side effects often leading to resistance to the parasites. Thus, it is essential to search for new treatment strategies, such as drug repurposing, i.e., the use of drugs that are already used for other diseases. The discovery of new clinical applications for approved drugs is strategic for lowering the cost of drug discovery since human toxicity assays are already conducted. Here, we review a broad analysis of the different aspects of this approach for anti-leishmanial treatment.

show abstract

The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis

Bezerra-Souza

Yamamoto

Laurenti

et al. 2016

Parasitology International

View full text Add to dashboard Cite

The production of ergosterol lipid, important for the Leishmania membrane homeostasis, involves different enzymes. This pathway can be blocked to azoles and allylamines drugs, such as Butenafine. The aim of the present work was to evaluate the anti-leishmanicidal activity of this drug in 2 major species of Leishmania responsible for causing the American tegumentar leishmaniasis (L. (L.) amazonensis and L. (V.) braziliensis). Butenafine eliminated promastigote forms of L. amazonensis and L. braziliensis with efficacy similar to miltefosine, a standard anti-leishmania drug. In addition, butenafine induced alterations in promastigote forms of L. amazonensis that resemble programmed cell death. Butenafine as well as miltefosine presented mild toxicity in peritoneal macrophages, however, butenafine was more effective to eliminate intracellular amastigotes of both L. amazonensis and L. braziliensis, and this effect was not associated with elevated levels of nitric oxide or hydrogen peroxide. Taken together, data presented herein suggests that butenafine can be considered as a prototype drug able to eliminate L. amazonensis and L. braziliensis, etiological agents of anergic diffuse and mucocutaneous leishmaniasis, respectively.

show abstract

Ineficácia in vivo da terbinafina em leishmaniose cutânea causada por Leishmania (Leishmania) amazonensis em camundongos C57BL/6

Cited by 7 publications

References 10 publications

Potencial anti-Leishmania e imunomodulador dos extratos de Campsiandra laurifolia Benth. (Fabaceae)

Potencial anti-Leishmania e imunomodulador dos extratos de Campsiandra laurifolia Benth. (Fabaceae)

Leishmaniasis treatment update of possibilities for drug repurposing

The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis

Contact Info

Product

Resources

About